1
|
Combemale P, Sonzogni L, Devic C, Bencokova Z, Ferlazzo ML, Granzotto A, Burlet SF, Pinson S, Amini-Adle M, Al-Choboq J, Bodgi L, Bourguignon M, Balosso J, Bachelet JT, Foray N. Individual Response to Radiation of Individuals with Neurofibromatosis Type I: Role of the ATM Protein and Influence of Statins and Bisphosphonates. Mol Neurobiol 2021; 59:556-573. [PMID: 34727321 DOI: 10.1007/s12035-021-02615-3] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Accepted: 10/21/2021] [Indexed: 11/26/2022]
Abstract
Neurofibromatosis type 1 (NF1) is a disease characterized by high occurrence of benign and malignant brain tumours and caused by mutations of the neurofibromin protein. While there is an increasing evidence that NF1 is associated with radiosensitivity and radiosusceptibility, few studies have dealt with the molecular and cellular radiation response of cells from individuals with NF1. Here, we examined the ATM-dependent signalling and repair pathways of the DNA double-strand breaks (DSB), the key-damage induced by ionizing radiation, in skin fibroblast cell lines from 43 individuals with NF1. Ten minutes after X-rays irradiation, quiescent NF1 fibroblasts showed abnormally low rate of recognized DSB reflected by a low yield of nuclear foci formed by phosphorylated H2AX histones. Irradiated NF1 fibroblasts also presented a delayed radiation-induced nucleoshuttling of the ATM kinase (RIANS), potentially due to a specific binding of ATM to the mutated neurofibromin in cytoplasm. Lastly, NF1 fibroblasts showed abnormally high MRE11 nuclease activity suggesting a high genomic instability after irradiation. A combination of bisphosphonates and statins complemented these impairments by accelerating the RIANS, increasing the yield of recognized DSB and reducing genomic instability. Data from NF1 fibroblasts exposed to radiation in radiotherapy and CT scan conditions confirmed that NF1 belongs to the group of syndromes associated with radiosensitivity and radiosusceptibility.
Collapse
Affiliation(s)
- Patrick Combemale
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1296 Research Unit « Radiation : Defense, Health and Environment », Centre Léon-Bérard, 69008, Lyon, France
- Centre Léon-Bérard, 69008, Lyon, France
| | - Laurène Sonzogni
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1296 Research Unit « Radiation : Defense, Health and Environment », Centre Léon-Bérard, 69008, Lyon, France
| | - Clément Devic
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1296 Research Unit « Radiation : Defense, Health and Environment », Centre Léon-Bérard, 69008, Lyon, France
| | - Zuzana Bencokova
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1296 Research Unit « Radiation : Defense, Health and Environment », Centre Léon-Bérard, 69008, Lyon, France
| | - Mélanie Lydia Ferlazzo
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1296 Research Unit « Radiation : Defense, Health and Environment », Centre Léon-Bérard, 69008, Lyon, France
| | - Adeline Granzotto
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1296 Research Unit « Radiation : Defense, Health and Environment », Centre Léon-Bérard, 69008, Lyon, France
| | - Steven Franck Burlet
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1296 Research Unit « Radiation : Defense, Health and Environment », Centre Léon-Bérard, 69008, Lyon, France
| | - Stéphane Pinson
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1296 Research Unit « Radiation : Defense, Health and Environment », Centre Léon-Bérard, 69008, Lyon, France
- Centre Léon-Bérard, 69008, Lyon, France
| | - Mona Amini-Adle
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1296 Research Unit « Radiation : Defense, Health and Environment », Centre Léon-Bérard, 69008, Lyon, France
- Centre Léon-Bérard, 69008, Lyon, France
| | - Joëlle Al-Choboq
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1296 Research Unit « Radiation : Defense, Health and Environment », Centre Léon-Bérard, 69008, Lyon, France
| | - Larry Bodgi
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1296 Research Unit « Radiation : Defense, Health and Environment », Centre Léon-Bérard, 69008, Lyon, France
| | - Michel Bourguignon
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1296 Research Unit « Radiation : Defense, Health and Environment », Centre Léon-Bérard, 69008, Lyon, France
- Université de Versailles-Saint Quentin en Yvelines, 78035, Versailles, France
| | - Jacques Balosso
- Service de Radiothérapie, CHU de Grenoble, 38042, Grenoble, France
| | - Jean-Thomas Bachelet
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1296 Research Unit « Radiation : Defense, Health and Environment », Centre Léon-Bérard, 69008, Lyon, France
| | - Nicolas Foray
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1296 Research Unit « Radiation : Defense, Health and Environment », Centre Léon-Bérard, 69008, Lyon, France.
| |
Collapse
|
2
|
El-Nachef L, Al-Choboq J, Restier-Verlet J, Granzotto A, Berthel E, Sonzogni L, Ferlazzo ML, Bouchet A, Leblond P, Combemale P, Pinson S, Bourguignon M, Foray N. Human Radiosensitivity and Radiosusceptibility: What Are the Differences? Int J Mol Sci 2021; 22:7158. [PMID: 34281212 PMCID: PMC8267933 DOI: 10.3390/ijms22137158] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2021] [Revised: 06/25/2021] [Accepted: 06/28/2021] [Indexed: 12/27/2022] Open
Abstract
The individual response to ionizing radiation (IR) raises a number of medical, scientific, and societal issues. While the term "radiosensitivity" was used by the pioneers at the beginning of the 20st century to describe only the radiation-induced adverse tissue reactions related to cell death, a confusion emerged in the literature from the 1930s, as "radiosensitivity" was indifferently used to describe the toxic, cancerous, or aging effect of IR. In parallel, the predisposition to radiation-induced adverse tissue reactions (radiosensitivity), notably observed after radiotherapy appears to be caused by different mechanisms than those linked to predisposition to radiation-induced cancer (radiosusceptibility). This review aims to document these differences in order to better estimate the different radiation-induced risks. It reveals that there are very few syndromes associated with the loss of biological functions involved directly in DNA damage recognition and repair as their role is absolutely necessary for cell viability. By contrast, some cytoplasmic proteins whose functions are independent of genome surveillance may also act as phosphorylation substrates of the ATM protein to regulate the molecular response to IR. The role of the ATM protein may help classify the genetic syndromes associated with radiosensitivity and/or radiosusceptibility.
Collapse
Affiliation(s)
- Laura El-Nachef
- Inserm, U1296 unit, Radiation: Defense, Health and Environment, Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France; (L.E.-N.); (J.A.-C.); Juliette.Restier-- (J.R.-V.); (A.G.); (E.B.); (L.S.); (M.L.F.); (A.B.); (M.B.)
| | - Joelle Al-Choboq
- Inserm, U1296 unit, Radiation: Defense, Health and Environment, Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France; (L.E.-N.); (J.A.-C.); Juliette.Restier-- (J.R.-V.); (A.G.); (E.B.); (L.S.); (M.L.F.); (A.B.); (M.B.)
| | - Juliette Restier-Verlet
- Inserm, U1296 unit, Radiation: Defense, Health and Environment, Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France; (L.E.-N.); (J.A.-C.); Juliette.Restier-- (J.R.-V.); (A.G.); (E.B.); (L.S.); (M.L.F.); (A.B.); (M.B.)
| | - Adeline Granzotto
- Inserm, U1296 unit, Radiation: Defense, Health and Environment, Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France; (L.E.-N.); (J.A.-C.); Juliette.Restier-- (J.R.-V.); (A.G.); (E.B.); (L.S.); (M.L.F.); (A.B.); (M.B.)
| | - Elise Berthel
- Inserm, U1296 unit, Radiation: Defense, Health and Environment, Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France; (L.E.-N.); (J.A.-C.); Juliette.Restier-- (J.R.-V.); (A.G.); (E.B.); (L.S.); (M.L.F.); (A.B.); (M.B.)
- Neolys Diagnostics, 67960 Entzheim, France
| | - Laurène Sonzogni
- Inserm, U1296 unit, Radiation: Defense, Health and Environment, Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France; (L.E.-N.); (J.A.-C.); Juliette.Restier-- (J.R.-V.); (A.G.); (E.B.); (L.S.); (M.L.F.); (A.B.); (M.B.)
| | - Mélanie L. Ferlazzo
- Inserm, U1296 unit, Radiation: Defense, Health and Environment, Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France; (L.E.-N.); (J.A.-C.); Juliette.Restier-- (J.R.-V.); (A.G.); (E.B.); (L.S.); (M.L.F.); (A.B.); (M.B.)
| | - Audrey Bouchet
- Inserm, U1296 unit, Radiation: Defense, Health and Environment, Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France; (L.E.-N.); (J.A.-C.); Juliette.Restier-- (J.R.-V.); (A.G.); (E.B.); (L.S.); (M.L.F.); (A.B.); (M.B.)
| | - Pierre Leblond
- Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France; (P.L.); (P.C.)
| | - Patrick Combemale
- Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France; (P.L.); (P.C.)
| | - Stéphane Pinson
- Hospices Civils de Lyon, Quai des Célestins, 69002 Lyon, France;
| | - Michel Bourguignon
- Inserm, U1296 unit, Radiation: Defense, Health and Environment, Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France; (L.E.-N.); (J.A.-C.); Juliette.Restier-- (J.R.-V.); (A.G.); (E.B.); (L.S.); (M.L.F.); (A.B.); (M.B.)
- Université Paris Saclay Versailles St Quentin en Yvelines, 78035 Versailles, France
| | - Nicolas Foray
- Inserm, U1296 unit, Radiation: Defense, Health and Environment, Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France; (L.E.-N.); (J.A.-C.); Juliette.Restier-- (J.R.-V.); (A.G.); (E.B.); (L.S.); (M.L.F.); (A.B.); (M.B.)
| |
Collapse
|
3
|
Azizi AA, Slavc I, Theisen BE, Rausch I, Weber M, Happak W, Aszmann O, Hojreh A, Peyrl A, Amann G, Benkoe TM, Wadsak W, Kasprian G, Staudenherz A, Hacker M, Traub-Weidinger T. Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [ 18 F]FDG-PET imaging. Is it of value in asymptomatic patients? Pediatr Blood Cancer 2018; 65. [PMID: 28771999 DOI: 10.1002/pbc.26733] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Revised: 06/20/2017] [Accepted: 07/02/2017] [Indexed: 12/27/2022]
Abstract
PURPOSE About 10% of patients with neurofibromatosis type 1 (NF-1) develop malignant peripheral nerve sheath tumours (MPNST) mostly arising in plexiform neurofibroma (PN); 15% of MPNST arise in children and adolescents. 2-[18 F]fluoro-2-deoxy-d-glucose ([18 F]FDG)-PET (where PET is positron emission tomography) is a sensitive method in differentiating PN and MPNST in symptomatic patients with NF-1. This study assesses the value of [18 F]FDG-PET imaging in detecting malignant transformation in symptomatic and asymptomatic children with PN. METHODS Forty-one patients with NF-1 and extensive PN underwent prospective [18 F]FDG imaging from 2003 to 2014. Thirty-two of the patients were asymptomatic. PET data, together with histological results and clinical course were re-evaluated retrospectively. Maximum standardised uptake values (SUVmax) and lesion-to-liver ratio were assessed. RESULTS A total of 104 examinations were performed. Mean age at first PET was 13.5 years (2.6-22.6). Eight patients had at least one malignant lesion; four of these patients were asymptomatic. Two of four symptomatic patients died, while all patients with asymptomatic malignant lesions are alive. All malignant tumours could be identified by PET imaging in both symptomatic and asymptomatic patients. All lesions judged as benign by [18 F]FDG imaging and clinical judgment were either histologically benign if removed or remained clinically silent during follow-up. SUVmax of malignant and benign lesions overlapped, but no malignant lesion showed FDG uptake ≤3.15. Asymptomatic malignant lesions were detected with a sensitivity of 100%, a negative predictive value of 100% and a specificity of 45.1%. CONCLUSION Malignant transformation of PN also occurs in asymptomatic children and adolescents. Detection of MPNST at early stages could increase the possibility of oncologically curative resections.
Collapse
Affiliation(s)
- Amedeo A Azizi
- Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
| | - Irene Slavc
- Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
| | - Benjamin Emile Theisen
- Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
| | - Ivo Rausch
- Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria
| | - Michael Weber
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Wolfgang Happak
- Department of Surgery, Medical University of Vienna, Vienna, Austria
| | - Oskar Aszmann
- Department of Surgery, Medical University of Vienna, Vienna, Austria
| | - Azadeh Hojreh
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Andreas Peyrl
- Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
| | - Gabriele Amann
- Department of Clinical Pathology, Medical University of Vienna, Vienna, Austria
| | - Thomas M Benkoe
- Department of Surgery, Medical University of Vienna, Vienna, Austria
| | - Wolfgang Wadsak
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Gregor Kasprian
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Anton Staudenherz
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Marcus Hacker
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Tatjana Traub-Weidinger
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
4
|
Abstract
Cells obtained on culture from normal appearing skin (NFns) and from neurofibromas of neurofibromatosis patients (NFnf), and from normal skin of normal donors (Normal) were studied. We measured the growth rate, maximal cell density, radiation sensitivity and resistance to 3-nitrotyrosine of each of the three groups of strains. The growth rate and maximal cell density of fibroblasts derived from neurofibromas of the neurofibromatosis patients were significantly lower than those in normal donors. The neurofibromatosis cells showed no X-ray hypersensitivity, as compared to normal controls. We also did not observe resistance to 3-nitrotyrosine of the cells derived from normal appearing skin of the neurofibromatosis patients. However, cells derived from neurofibromas of the neurofibromatosis patients showed resistance to 3-nitrotyrosine. This phenomenon may explain the slow growth rate of the latter cells.
Collapse
Affiliation(s)
- A Hayashi
- Division of Mental Retardation and Birth Defects Research, National Institute of Neuroscience, Tokyo, Japan
| | | |
Collapse
|
5
|
Krone W, Mao R, Mühleck OS, Kling H, Fink T. Cell culture studies on neurofibromatosis (von Recklinghausen). Characterization of cells growing from neurofibromas. Ann N Y Acad Sci 1986; 486:354-70. [PMID: 3105399 DOI: 10.1111/j.1749-6632.1986.tb48089.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|